UBS Says Impax 'Ahead Of Itself,' Downgrades To Sell
April 17, 2015 at 10:52 AM EDT
UBS downgraded Impax Laboratories Inc (NASDAQ: IPXL) Thursday from Neutral to Sell and maintained a $36 price target. Analyst ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.